Copyright
©2014 Baishideng Publishing Group Co.
World J Hepatol. Apr 27, 2014; 6(4): 160-168
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.160
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.160
AIH with DILI | Patients with known AIH AIH quiescent: the drug may be the trigger of a new bout AIH under IS or corticosteroids treatment: Reactivation of known AIH upon intro duction of a newdrug (very difficult to demonstrate a causal relationship as it might be coincidental Often advanced fibrosis on histology |
DI-AIH | Patients with a low grade disease not diagnosed before or predisposition to AIH Drug produce an immune reaction that lead to a chronic process: Perpetuating the AIH Permanent need of IS Habitually typical HLA-DR associated |
IM-DILI (Autoimmune hypersensitivity) | Fever, eosinophilia, lymphadenopathy, rush Indistinguishable from true AIH: Mandatory IS treatment Frequently spontaneous remission after drug cessation Usually complete response to treatment and sustained remission without relapse It is the most frequent drug-induced immune process in the liver attributable to drugs |
Mixed autoimmune type | Patients with mixed clinical features of DI-AIH and IM-DILI Complete response to IS treatment but with chronic course after withdrawal Patients under IS treatment for another autoimmune disease. Withdraw IS drugs is not possible. Remission cannot be evaluated |
DILI with positive autoantibodies | Patients with positive autoantibodies The probability of developing DIAILD increases in second DILI episodes indepe dently of the causal agent |
Previously obtained ANA |
Evolution: |
During the treatment with the suspicious drug |
After drug withdrawal |
Check for the presence of HLA-DR: |
HLA-DRB1*0301,0401,07,1301 |
Drug type |
Time to onset from the beginning of the treatment |
AIH diagnosed: |
During the course of treatment |
After withdrawal of the drug |
AIH scales for diagnosis |
International autoimmune hepatitis group report (4) |
Simplified score (5) |
Previous DILI episodes |
Response to corticosteroids |
Autoimmune titres evolution |
IgG values evolution |
Well stablished drugs: |
Minocycline |
Nitrofurantoin |
Oxyphenisatin, alpha-methyl-dopa, clometacin. |
Emerging drugs: |
Statins |
Biologics agents: |
Infliximab |
Others: adalimumab, etanercept, efalizumab, ipilimumab |
Other drugs: |
Less compelling association (infrequent reports): atomoxetine, diclofenac, fenofibrate, pemoline, phenprocoumon, dihydralazine, tielinic acid, benzarone |
- Citation: Castiella A, Zapata E, Lucena MI, Andrade RJ. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J Hepatol 2014; 6(4): 160-168
- URL: https://www.wjgnet.com/1948-5182/full/v6/i4/160.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i4.160